Table 9. Univariate and multivariate analyses of prognostic factors for LRFS, LRRFS, and DMFS of patients in the BCS group.
| Variable | LRFS | LRRFS | DMFS | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | ||||||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||||
| Age at diagnosis, years | |||||||||||||||||
| <40 | Ref | Ref | Ref | ||||||||||||||
| 40–59 | 0.638 (0.283–1.437) | 0.278 | 0.533 (0.180–1.577) | 0.256 | 0.729 (0.331–1.608) | 0.434 | 0.544 (0.186–1.593) | 0.267 | 0.442 (0.155–1.261) | 0.127 | 0.662 (0.163–2.685) | 0.564 | |||||
| ≥60 | 0.581 (0.160–2.113) | 0.410 | 0.713 (0.115–4.427) | 0.716 | 0.589 (0.162–2.142) | 0.422 | 0.820 (0.140–4.811) | 0.826 | 0.539 (0.112–2.597) | 0.441 | 1.326 (0.121–14.480) | 0.817 | |||||
| BC with DCIS vs. BC without DCIS | 0.418 (0.191–0.914) | 0.029 | 0.441 (0.137–1.417) | 0.169 | 0.375 (0.174–0.807) | 0.012 | 0.423 (0.136–1.317) | 0.137 | 0.583 (0.217–1.565) | 0.284 | 0.277 (0.061–1.263) | 0.097 | |||||
| MTD | 1.392 (1.076–1.802) | 0.012 | 1.449 (1.010–2.078) | 0.044 | 1.395 (1.089–1.788) | 0.008 | 1.465 (1.027–2.090) | 0.035 | 1.398 (1.018–1.921) | 0.039 | 1.270 (0.783–2.059) | 0.333 | |||||
| RV | 1.004 (1.001–1.008) | 0.014 | 1.009 (1.003–1.016) | 0.004 | 1.004 (1.001–1.008) | 0.011 | 1.010 (1.004–1.017) | 0.002 | 1.005 (1.001–1.009) | 0.021 | 1.004 (0.998–1.010) | 0.197 | |||||
| N stages | |||||||||||||||||
| N0 | Ref | Ref | Ref | ||||||||||||||
| N1 | 1.389 (0.524–3.685) | 0.509 | 2.928 (0.676–12.688) | 0.151 | 1.660 (0.670–4.114) | 0.273 | 2.955 (0.689–12.671) | 0.145 | 2.213 (0.587–8.345) | 0.241 | 7.763 (1.213–49.687) | 0.030 | |||||
| N2 | 1.101 (0.148–8.191) | 0.925 | 0.347 (0.015–8.160) | 0.511 | 1.098 (0.148–8.171) | 0.927 | 0.255 (0.009–7.044) | 0.420 | 14.161 (4.258–47.100) | <0.001 | 27.044 (2.469–296.165) | 0.007 | |||||
| N3 | 0 | 0.981 | 0 | 0.987 | 11.551 (1.499–89.022) | 0.019 | 29.001 (2.473–340.105) | 0.007 | 22.755 (2.751–188.230) | 0.004 | 43.841 (2.569–748.008) | 0.009 | |||||
| Nodal surgery | |||||||||||||||||
| SLNB | Ref | Ref | Ref | ||||||||||||||
| ALND | 0.505 (0.219–1.163) | 0.108 | 0.265 (0.077–0.920) | 0.036 | 0.584 (0.258–1.320) | 0.196 | 0.262 (0.076–0.903) | 0.034 | 0.938 (0.297–2.960) | 0.913 | 0.240 (0.040–1.435) | 0.118 | |||||
| None | 1.470 (0.397–5.446) | 0.564 | 5.569 (0.569–54.511) | 0.140 | 1.449 (0.391–5.366) | 0.578 | 5.312 (0.535–52.741) | 0.154 | 0.977 (0.109–8.756) | 0.983 | 0 | 0.989 | |||||
| IMA | |||||||||||||||||
| GE vs. FS | 1.461 (0.505–4.226) | 0.484 | 1.940 (0.504–7.460) | 0.335 | 1.342 (0.467–3.856) | 0.585 | 1.909 (0.493–7.392) | 0.349 | 1.236 (0.281–5.438) | 0.779 | 1.991 (0.391–10.134) | 0.407 | |||||
| Radiotherapy | |||||||||||||||||
| No vs. yes | 1.706 (0.636–4.575) | 0.288 | 2.009 (0.444–9.092) | 0.365 | 1.860 (0.700–4.937) | 0.213 | 1.933 (0.442–8.447) | 0.381 | 0.568 (0.160–2.014) | 0.381 | 0.656 (0.115–3.742) | 0.635 | |||||
| Endocrine therapy | |||||||||||||||||
| No vs. yes | 1.846 (0.665–5.126) | 0.240 | 2.573 (0.785–8.434) | 0.119 | 2.003 (0.728–5.512) | 0.179 | 2.837 (0.852–9.449) | 0.089 | 0.288 (0.063–1.316) | 0.108 | 2.924 (0.598–14.308) | 0.185 | |||||
LRFS, local recurrence-free survival; LRRFS, local-regional recurrence-free survival; DMFS, distant metastasis-free survival; BCS, breast-conserving surgery; BC, breast-cancer; DCIS, ductal carcinoma in situ; MTD, maximum tumor diameter; RV, resection volume; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; IMA, intraoperative margin assessment; GE, gross examination; FS, frozen section; Ref, reference group.